V. Wacher

发表

Inhibiting efflux with novel non-ionic surfactants: Rational design based on vitamin E TPGS.

James L. Little, M. Wempe, C. M. Buchanan, 2009, International journal of pharmaceutics.

Grapefruit Juice Activates P-Glycoprotein-Mediated Drug Transport

U. Christians, L. Benet, A. Soldner, 1999, Pharmaceutical Research.

Selection of a cut-off for high- and low-methane producers using a spot-methane breath test: results from a large north American dataset of hydrogen, methane and carbon dioxide measurements in breath

K. Gottlieb, Chenxiong C. Le, J. Sliman, 2017, Gastroenterology report.

Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial.

Heidi Whalen, Chenxiong C. Le, J. Sliman, 2019, The Lancet. Infectious diseases.

Sirolimus Oral Absorption in Rats Is Increased by Ketoconazole but Is Not Affected by d-α-Tocopheryl Poly(Ethylene Glycol 1000) Succinate

Susan D. Wong, J. Silverman, Xiang-Qing Yu, 2002, Journal of Pharmacology and Experimental Therapeutics.

Lovastatin lactone may improve irritable bowel syndrome with constipation (IBS-C) by inhibiting enzymes in the archaeal methanogenesis pathway

Steven M. Muskal, K. Gottlieb, S. Muskal, 2016, F1000Research.

Efficacy and Safety of Oral Methazolamide in Patients With Type 2 Diabetes: A 24-Week, Placebo-Controlled, Double-Blind Study

N. Orford, J. Proietto, G. Krippner, 2014, Diabetes Care.

Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin.

M. Wempe, N. Buchanan, K. Edgar, 2008, International journal of pharmaceutics.

Pharmacokinetics of tamoxifen after intravenous and oral dosing of tamoxifen-hydroxybutenyl-beta-cyclodextrin formulations.

M. Wempe, N. Buchanan, J. Little, 2007, Journal of pharmaceutical sciences.

Pharmacokinetics of itraconazole after intravenous and oral dosing of itraconazole-cyclodextrin formulations.

James L. Little, M. Wempe, S. Klein, 2007, Journal of pharmaceutical sciences.

Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics.

Y Zhang, L. Benet, L Z Benet, 1998, Journal of pharmaceutical sciences.

The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine

L. Benet, M. Hebert, S. Tomlanovich, 1995, Clinical pharmacology and therapeutics.

Active secretion and enterocytic drug metabolism barriers to drug absorption.

L. Benet, L. Salphati, V. Wacher, 2001, Advanced drug delivery reviews.

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy

L. Benet, L Z Benet, C Y Wu, 1995, Molecular carcinogenesis.

Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo

G. Dresser, D. Bailey, Susan D. Wong, 2002, Clinical pharmacology and therapeutics.

Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole.

Susan D. Wong, V. Wacher, H. Wong, 2002, Journal of pharmaceutical sciences.

Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: Studies with cyclosporine

M Rowland, L. Benet, M. Hebert, 1995, Clinical pharmacology and therapeutics.

Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery.

Y Zhang, L. Benet, T. Izumi, 1999, Journal of controlled release : official journal of the Controlled Release Society.

Active secretion and enterocytic drug metabolism barriers to drug absorption 1 PII of original artic

L. Benet, L. Salphati, V. Wacher, 1996 .

Intestinal drug metabolism and antitransport processes : A potential paradigm shift in oral drug delivery

Leslie Z. Benet, L. Benet, M. Hebert, 1996 .

A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer

M. J. Newman, K. Gelmon, B. Sikic, 2005, Investigational New Drugs.

Minimal effect of ketoconazole on cyclosporine (SangCyATM) oral absorption and first‐pass metabolism in rats: evidence of a significant vehicle effect on SangCyA absorption

Susan D. Wong, V. Wacher, H. Wong, 2002, Biopharmaceutics & drug disposition.

Pharmacokinetics of saquinavir after intravenous and oral dosing of saquinavir: hydroxybutenyl-beta-cyclodextrin formulations.

M. Wempe, N. Buchanan, J. Little, 2008, Biomacromolecules.

2-Aryl-5-tert-butyl-1,3-dithianes and their S-oxidation products : structure-activity relationships of potent insecticides acting at the GABA-gated chloride channel

J. Casida, R. Toia, V. Wacher, 1992 .

Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders

K. Gottlieb, M. Pimentel, J. Sliman, 2015, Alimentary pharmacology & therapeutics.

Development of a Modified-Release Formulation of Lovastatin Targeted to Intestinal Methanogens Implicated in Irritable Bowel Syndrome With Constipation.

V. Wacher, J. Kokai-Kun, A. Bristol, 2018, Journal of pharmaceutical sciences.

Time course of cyclosporine and its metabolites in blood, liver and spleen of naive lewis rats: Comparison with preliminary data obtained in transplanted animals

L. Benet, J. Roberts, N. Ascher, 1995, Biopharmaceutics & drug disposition.

X-Ray Crystal-Structure of 5-Acetoxymethyl-5-methyl-2-phenyl-1,3,2-dioxaphosphorinane 2-Oxide

D. Craig, R. Toia, V. Wacher, 1989 .

Lovastatin lactone may improve irritable bowel syndrome with constipation (IBS-C) by inhibiting enzymes in the archaeal methanogenesis pathway [version 1; peer review: 1 approved with reservations]

Steven M. Muskal, V. Wacher, J. Kokai-Kun, 2022 .